Munjid Al Harthy, M.D.

Munjid Al Harthy, M.D.
Assistant Research Physician

Dr. Al Harthy is a medical oncologist who specializes in the treatment of genitourinary malignancies. His clinical research interest focuses on developing novel approaches to treat patients with renal cell cancer using combination therapies, including immunotherapy, targeted therapy, chemotherapy and therapeutic cancer vaccines. Previously, Dr. Al Harthy worked with the Genitourinary Malignancies Branch on various prostate cancer protocols and enjoys being part of a multidisciplinary team that treats patients with both common and rare hereditary cancer syndromes.

Areas of Expertise

1) genitourinary malignancies, 2) clinical trials, 3) kidney cancer,  4) prostate cancer, 5) immunotherapy, 6) targeted therapy

Contact Info

Munjid Al Harthy, M.D.
Center for Cancer Research
National Cancer Institute
Building 10, Room 3D-37
Bethesda, MD 20892
Ph: 301-496-4000

Selected Recent Publications

  1. Al Harthy M, Redman J, Madan R.
    Expert Opin Biol Ther. Epub ahead of print (Jan 27), 2020. [ Journal Article ]
  2. A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C+DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC).
    Al Harthy M, Madan RA, Karzai F, Dahut W et al.
    J Clin Oncol. 2019. [ Journal Article ]
  3. Efficacy of abiraterone and enzalutamide in patients who had disease progression within twelve months of completing docetaxel for metastatic castration sensitive prostate cancer.
    Gang C, VanderWeele DJ, Karzai F, Bilusic MAl Harthy M, Arlen PM, Rosner IL, Chun G, Owens H, Couvillon A, Hankin A, Williams M, Cordes LM, Figg WD, Gulley JL, Dahut WL, Madan RA.
    J Clin Oncol. 2019. [ Journal Article ]
  4. Intermittent Short Course Enzalutamide in Biochemically Recurrent Prostate Cancer: Analysis of PSA Recovery, Testosterone Level and Tolerability.
    Al Harthy M, Singh H, Karzai F, Arlen PM, Theoret MR, Marte J, Bilusic M, Couvillon A, Owens H, Hankin A, Cordes L, Rosner I, Strauss J, Figg WD, Schlom J, Dahut W, Gulley J, Madan RA.
    Ann Oncol. 2018. [ Journal Article ]
  5. Pallazola VA, Murray JC, Al Harthy M, Zimmerman SL, Webster J, Gondek LP.
    Am J Hematol. 93(3): 469-470, 2018. [ Journal Article ]

Dr Al Harthy received his M.D. from the Weill Cornell Medical College. He subsequently completed his internal medicine residency at the Rochester General Hospital in Rochester, NY, and a fellowship in medical oncology and hematology at the National Cancer Institute (NCI) and National Health, Lung, and Blood Institute (NHLBI) in Bethesda, MD, respectively. During his fellowship training, he completed a certificate program in Clinical and Translational Research from the NIH-Duke University School of Medicine Clinical Research Training Program. Dr. Al Harthy worked in CCR's Genitourinary Malignancies Branch on prostate cancer clinical trials and later joined the Urologic Oncology Branch as an Assistant Research Physician focusing on kidney cancer protocols. He is American board certified in internal medicine and medical oncology.